Cel-Sci
CVM
$1.67
Share price
-2.91%
Change (1 day)
-33.20%
Change (1 year)
Categories
Cel-Sci (CVM) - Total liabilities
Total liabilities on the balance sheet as of December 2023 : $16.06 M
According to Cel-Sci 's latest financial reports the company's total liabilities are $16.06 M. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Cel-Sci - Total liabilities on balance sheet (from 2001 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-09-30 | $17.31 M | -5.7% |
| 2022-09-30 | $18.36 M | -5.04% |
| 2021-09-30 | $19.33 M | -7.08% |
| 2020-09-30 | $20.8 M | -7.47% |
| 2019-09-30 | $22.48 M | -23.99% |
| 2018-09-30 | $29.58 M | 12.66% |
| 2017-09-30 | $26.26 M | 2.72% |
| 2016-09-30 | $25.56 M | -23.26% |
| 2015-09-30 | $33.31 M | 279.15% |
| 2014-09-30 | $8.78 M | 112.33% |
| 2013-09-30 | $4.13 M | -54.22% |
| 2012-09-30 | $9.04 M | -5.31% |
| 2011-09-30 | $9.54 M | -4.06% |
| 2010-09-30 | $9.95 M | -73.24% |
| 2009-09-30 | $37.18 M | 866.49% |
| 2008-09-30 | $3.84 M | -36.52% |
| 2007-09-30 | $6.06 M | -42.74% |
| 2006-09-30 | $10.58 M | 971.99% |
| 2005-09-30 | $0.98 M | -29.05% |
| 2004-09-30 | $1.39 M | -17.67% |
| 2003-09-30 | $1.69 M | -37.61% |
| 2002-09-30 | $2.7 M | 433.57% |
| 2001-09-30 | $0.5 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $101.94 B | 634,682.07% | 🇺🇸 USA |
 Amgen AMGN | $90.92 B | 566,039.48% | 🇺🇸 USA |
 Xencor XNCR | $0.28 B | 1,665.62% | 🇺🇸 USA |
 Curis CRIS | $57.61 M | 258.73% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $35.35 B | 220,030.76% | 🇮🇱 Israel |
 BioCryst Pharmaceuticals
BCRX | $0.97 B | 5,955.34% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | $1.17 B | 7,209.46% | 🇺🇸 USA |
 Eterna Therapeutics ERNA | $46.89 M | 192.02% | 🇺🇸 USA |